Annet Nanduudu

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

Pauline Bollen, Cecilia L. Moore, Hilda Mujuru et al. · The Lancet HIV · 2020 · 49 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Hylke Waalewijn, Man K. Chan, Pauline Bollen et al. · The Lancet HIV · 2022 · 38 citations · Full text

Pharmacy, Pediatrics, Pharmacokinetics +14

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Amuge, Abbas Lugemwa, Ben Wynne et al. · The Lancet HIV · 2022 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pediatrics +15

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

Anna Turkova, Cecilia L. Moore, Karina Butler et al. · PLoS ONE · 2018 · 29 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +17

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan et al. · The Lancet HIV · 2022 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17